Oncura, a supplier of brachytherapy products, has been awarded the contract with The London Clinic – an independent hospital – to provide radioactive seeds for their new low dose rate (LDR) brachytherapy service for the treatment of prostate cancer, one of the commonest forms of cancer in men.
LDR brachytherapy is a proven, cost-effective treatment for early, localised prostate cancer.
It is minimally invasive and involves implanting tiny radioactive seeds through fine needles into the prostate to destroy the cancer cells. Its side-effect profile offers patients less risk of impotence and incontinence after treatment, compared to other treatment options.
The procedure is carried out under general anaesthetic and most patients go home the following day.
